It is an exciting time for tau researchers as it is now generally accepted that abnormal tau species are required to mediate the toxic effects of amyloid β-peptide oligomers in Alzheimer's disease. Tau may play multiple roles in neurophysiology and there may be further pathologically relevant tau alterations, besides hyperphosphorylation and aggregation. The recent Biology and Pathology of Tau and its Role in Tauopathies II meeting explored these various aspects of tau, and presentations at the meeting, described in the following articles in this issue of Biochemical Society Transactions, are outlined in the present paper.
Following the success in 2010 of the first Biochemical Society Focused Meeting on tau, 2012 saw the second Biology and Pathology of Tau and its Role in Tauopathies meeting. Like the previous meeting, it featured contributions from multiple invertebrate and vertebrate experimental models, human geneticists, neurologists and pharmacologists. As established in the inaugural meeting, this meeting was also punctuated with open discussions, debates and brainstorming sessions aiming to decipher the elusive functions of the MT (microtubule)-associated protein tau in normal neuronal physiology and its role in the pathology of tauopathies. The findings from these presentations are described in more detail in the ensuing papers of this issue of Biochemical Society Transactions, so this overview aims to summarize highlights of the two-day meeting.
Tauopathies are characterized by insoluble aggregates of tau and the pathological consequences of tau aggregation were discussed and debated following presentations from the Goedert and Mandelkow [1] a tight causal relationship between aggregation of tau and neurodegeneration.
However, whether aggregation of tau into insoluble particles is necessary for its toxicity, and whether toxicity can also be mediated by soluble and insoluble pre-filament tau oligomers was hotly debated following presentations from the Binder [2] , Takashima [3] and Mudher [4] groups. Tau oligomers, like Aβ (amyloid β-peptide) oligomers are now emerging as important contributors to tau toxicity, but because they can exist in a variety of states (they have been found to be both soluble and insoluble and both non-phosphorylated and hyperphosphorylated), their role in tauopathies is likely to be complex. Some even argue that formation of large tau oligomers may be a protective strategy of the dysfunctional neuron to sequester and eventually clear the more toxic soluble tau monomers and oligomers.
In a similar vein, the pathological significance of sitespecific phosphorylation of tau in tauopathies was eagerly discussed. Presentations from the groups of Skoulakis [5] and Jackson [6] clearly demonstrate that phosphorylation is not a 'one-size-fits-all' phenomenon. These findings also highlighted the leading edge that Drosophila models of tauopathy have in this field because of their genetic tractability which enabled the generation of site-specific phospho-mutant strains for these investigations. Similar investigations are slowly beginning in rodent models too, so we may better understand which tau phospho-sites mediate dysfunction, which mediate aggregation and which mediate toxicity.
Novel functions of tau and novel mechanisms of its toxicity were also discussed following presentations from the Avila laboratory [7] . Apparently, tau is exocytosed and endocytosed, highlighting mechanisms of tauopathy spreading through a patient's brain from a particular locus that harboured the initial event that yielded pathological tau. The potential role of the locus coeruleus as such a focal point was discussed by the Attems laboratory [8] . Moreover, the subneuronal localization and potential role in dysfunction and toxicity of specific proteolytic tau peptides were presented by the Novák group [9] . This work complemented nicely data from the Binder [2] laboratory indicating roles in subneuronal localization and in the pathology of the relatively unstudied N-terminus of tau. These two reports underscored the essential contribution of novel monoclonal antibodies to less well known phosphorylation and structural changes to further our understanding of physiological and pathological tau species.
Interactions between tau and Aβ and the possible relationship between the two in AD (Alzheimer's disease), is very intensively investigated by researchers in the AD community. Presentations from the Wade-Martins [10] and Sotiropoulos [11] laboratories prompted discussions about this topic and led to interesting questions about non-MTstabilizing roles of tau in dendritic physiology.
Insights into the genetics of tauopathies and what they tell us about disease pathogenesis were provided by the presentations from the Hardy, Rovelet-Lecrux [12] and Gallo [13] groups. It is intriguing that mutations in the tau gene have still not been reported in AD, but how other variations in the tau gene itself can precipitate developmental and behavioural pathologies distinct from the typical constellation of tauopathies was debated. Independent genes were discussed that affect, influence or regulate tau isoform expression and copy number.
No such tau-based meeting would be complete without discussions of tau-based therapies. The presentations from the groups of Brunden [14] and Schmid [15] stimulated debate about the use of MT-stabilizing drugs and kinase inhibitors. The Brunden laboratory used rodent models to show the effectiveness of small brain-penetrant MT-stabilizing drugs [14] , whereas the Schmid laboratory used a zebrafish model to explore the utility of GSK3β (glycogen synthase kinase 3β) inhibitors [15] .
A clear and encompassing highlight of this meeting was that lessons learnt from simpler models can be extrapolated to inform and guide not only experiments performed in higher animals to understand tauopathies, but also the discovery of neuroprotective strategies to ameliorate them, as was nicely demonstrated by the Kraemer laboratory [16] .
Last, but certainly not least, were the contributions in the poster format that detailed discoveries of tauopathy mechanisms including interactions with novel proteins contributing to physiological and pathological functions, genetics and pharmacogenetics. The value of these contributions which provided additional discussion time was apparent as the poster area remained busy throughout both formal sessions and during breaks. This is an exciting time for tau biologists because it is now generally accepted that abnormal tau species are required to mediate the toxic effects of Aβ oligomers in AD. Coupled to this is the realization that tau may play multiple roles in neurophysiology and that all these should be affected by the disease-associated changes in tau. Also emerging is an appreciation of the fact that there may be more changes in tau, other than hyperphosphorylation and aggregation, which could all have pathological relevance, potentially characteristic of the various tauopathies. These thoughts and provocative debate and discussions lead us to believe that these meetings will continue in years to come and, if so, they promise that the third tau meeting will be a charm.
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